Statute Details
- Title: Medicines (Non-Medicinal Products) Order 2023
- Act Code: MA1975-S805-2023
- Legislation Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act 1975
- Power Used: Section 3(4)(c) of the Medicines Act 1975
- Commencement: 18 December 2023
- Enacting Instrument Date: Made on 20 November 2023
- Legislation Number: S 805/2023
- Status: Current version as at 27 March 2026
- Key Provisions (from extract): Sections 1–3 (Citation and commencement; definition exclusion; revocation)
- Related Legislation: Health Products Act 2007; Medicines Act 1975
What Is This Legislation About?
The Medicines (Non-Medicinal Products) Order 2023 is a short but legally significant instrument. Its core function is to clarify what does not count as a “medicinal product” for the purposes of the Medicines Act 1975. In practical terms, it draws a boundary between regulated “medicinal products” and certain substances that are instead treated as inputs for “health products” under the Health Products Act 2007.
Singapore’s regulatory framework distinguishes between different categories of regulated products. Medicines are subject to one regulatory regime, while health products (including certain supplements and related categories) are governed under a separate regime. This Order ensures that substances or compounds that are usable in manufacturing a health product—specifically, those that are pharmacologically active constituents—are not pulled into the medicines regime merely because they are chemically capable of being used in manufacture.
For lawyers advising manufacturers, importers, distributors, or compliance teams, the Order matters because classification affects licensing requirements, regulatory approvals, labelling and advertising controls, and enforcement risk. A substance’s regulatory “home” can change depending on how it is characterised in law—particularly whether it is treated as a medicinal product or as a constituent for a health product.
What Are the Key Provisions?
Section 1 (Citation and commencement) provides the formal identification and timing of the instrument. The Order is cited as the “Medicines (Non-Medicinal Products) Order 2023” and comes into operation on 18 December 2023. For practitioners, the commencement date is relevant when assessing compliance for activities conducted before and after that date (for example, whether a particular product classification should have been assessed under the earlier “Consolidation” Order).
Section 2 (Substances and articles that are not medicinal products for purposes of Act) is the substantive provision. It states that, for the purposes of the Medicines Act 1975, the term “medicinal product” does not include “any substance or compound that is usable in the manufacture of a health product” within the meaning of section 2(1) of the Health Products Act 2007 as a pharmacologically active constituent.
This wording is doing several legal tasks at once:
- It creates an exclusion from the Medicines Act 1975 definition of “medicinal product.” That means the excluded substances are not treated as medicinal products for the purposes of that Act.
- It ties the exclusion to “health product” manufacturing under the Health Products Act 2007. The phrase “usable in the manufacture of a health product” anchors the analysis in the Health Products Act’s definitional framework.
- It focuses on “pharmacologically active constituent”. This is important because pharmacological activity is often associated with medicinal effects. The Order clarifies that even if a constituent is pharmacologically active, it may still fall outside the medicines regime if it is used as a constituent for a health product (as defined in the Health Products Act 2007).
Section 3 (Revocation) revokes an earlier instrument: the Medicines (Non-Medicinal Products) (Consolidation) Order (O 3). Revocation is legally significant because it replaces the earlier classification rule with the 2023 Order. Practitioners should therefore treat the 2023 Order as the operative statement of the exclusion, subject to any later amendments or subsequent instruments.
Although the extract is brief, the legal effect is meaningful: it reduces regulatory ambiguity by specifying that certain substances used as pharmacologically active constituents in health product manufacture are not “medicinal products” under the Medicines Act 1975. This can be crucial in disputes or compliance assessments where the same chemical substance might otherwise be argued to fall within the medicines definition.
How Is This Legislation Structured?
The Order is structured as a three-section subsidiary legislation instrument:
- Section 1: Citation and commencement (administrative and temporal scope).
- Section 2: Substantive exclusion rule—what substances and compounds are not “medicinal products” for the purposes of the Medicines Act 1975.
- Section 3: Revocation of the earlier “Consolidation” Order.
In other words, the instrument is not a comprehensive regulatory code. It is a targeted definitional clarification that operates within the broader statutory architecture created by the Medicines Act 1975 and the Health Products Act 2007.
Who Does This Legislation Apply To?
This Order applies to persons and entities whose activities fall within the regulatory scope of the Medicines Act 1975—particularly where classification of a substance or compound as a “medicinal product” is relevant. While the Order does not directly impose licensing duties in the extract, it affects how the Medicines Act 1975 applies by carving out certain substances from the “medicinal product” category.
In practice, the Order is most relevant to:
- Manufacturers and formulators of health products who use pharmacologically active constituents.
- Importers and distributors of raw materials or ingredients that are intended for use in health product manufacture.
- Regulatory compliance teams and legal counsel advising on whether a substance triggers medicines regulatory requirements or remains within the health products framework.
The key practical point is that the exclusion is conditional: the substance must be “usable in the manufacture of a health product” and must be used as a “pharmacologically active constituent” within the meaning of the Health Products Act 2007. Therefore, applicability depends on intended use and regulatory characterisation, not merely on the chemical identity alone.
Why Is This Legislation Important?
First, the Order provides a clear legal boundary between the medicines and health products regimes. Without such an exclusion, there is a risk that pharmacologically active substances could be treated as medicinal products under the Medicines Act 1975, even when they are legitimately used as constituents in health products. That would potentially lead to unnecessary regulatory burdens and compliance uncertainty.
Second, the Order supports regulatory coherence. It recognises that “pharmacologically active” does not automatically mean “medicinal product” in the legal sense. By linking the exclusion to the Health Products Act 2007 definition of health products and to the concept of pharmacologically active constituents, the Order ensures that the classification system is consistent and that the regulatory framework can be applied predictably.
Third, for enforcement and risk management, the Order can materially affect outcomes. If a substance is correctly characterised as excluded under section 2, the Medicines Act 1975 may not apply in the same way. Conversely, if a substance is not “usable in the manufacture of a health product” or is not used as a pharmacologically active constituent within the statutory meaning, the exclusion may not apply, and medicines regulatory requirements could become relevant. Lawyers advising clients should therefore focus on evidence and documentation supporting intended use in health product manufacture, as well as careful alignment with the Health Products Act 2007 definitions.
Finally, the revocation in section 3 means practitioners should update internal regulatory matrices and compliance policies. Where older references to the “Medicines (Non-Medicinal Products) (Consolidation) Order (O 3)” exist, they should be replaced with the 2023 Order as the current legal basis for the exclusion.
Related Legislation
- Health Products Act 2007
- Medicines Act 1975
Source Documents
This article provides an overview of the Medicines (Non-Medicinal Products) Order 2023 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.